Advertisement

Topics

Ultragenyx’s UX007 Granted FDA Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Long-Chain Fatty Acid Oxidation Disorders

12:11 EDT 16 Apr 2019 | Speciality Pharma Journal

NOVATO, Calif., April 16, 2019 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Rare Pediatric Disease designation to UX007 for the treatment …

Original Article: Ultragenyx’s UX007 Granted FDA Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Long-Chain Fatty Acid Oxidation Disorders

NEXT ARTICLE

More From BioPortfolio on "Ultragenyx’s UX007 Granted FDA Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Long-Chain Fatty Acid Oxidation Disorders"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...